Myeloid Leukemia News and Research

RSS

Myeloid Leukemia is an aggressive (fast-growing) disease in which too many myeloblasts (immature white blood cells that are not lymphoblasts) are found in the bone marrow and blood. Also called acute myeloblastic leukemia, acute myelogenous leukemia, acute nonlymphocytic leukemia, AML, and ANLL.

New study offers insight into how high-risk form of blood cancer can develop in children

In some children with acute myeloid leukemia, cancer cells have the same amount of DNA changes as healthy blood stem cells.

6 Aug 2021

Scientists identify new therapeutic target for several aggressive cancers

A protein in tumor cells could be targeted to treat some types of aggressive cancer including brain, blood, skin, and kidney, new research has shown.

4 Aug 2021

Comprehensive genomic sequencing essential to capitalize precision medicine for pediatric cancer care

St. Jude Children's Research Hospital investigators have demonstrated that comprehensive genomic sequencing of all pediatric cancer patients is feasible and essential to capitalize on the lifesaving potential of precision medicine.

26 Jul 2021

Combination of investigational therapeutic and chemotherapy shows promise for AML treatment

The investigational therapeutic ficlatuzumab in combination with chemotherapy showed signs of clinical efficacy in patients with relapsed/refractory acute myeloid leukemia.

16 Jul 2021

Researchers unravel mechanisms that produce individualized metabolism in leukemia

A research collaboration based in Kumamoto University (Japan) has shown that lysine-specific demethylase 1 (LSD1), an enzyme involved in gene expression, produces individualized metabolism depending on the type of acute myeloid leukemia cells.

6 Jul 2021

A new study reveals unintended CRISPR/Cas9 editing events

A recent study by researchers from Sweden and the United Kingdom shows that CRISPR/Cas9-based genomic engineering can prompt unwanted on-target effects, and highlights the complexity of human DNA repair mechanisms in the presence of the powerful prokaryotic Cas9 nuclease. The paper is currently available on the bioRxiv* preprint server.

4 Jul 2021

Two CU Cancer Center studies provide insights into the link between inflammation and leukemia

Two recent collaborative publications by CU Cancer Center members provide insights into how chronic inflammation can serve as a key factor in the development of leukemia and other blood cancers.

29 Jun 2021

Study maps potential link between oil and gas production and childhood leukemia risk

A pilot study of childhood leukemia patients living near Colorado's oil and gas drilling sites recently led to an American Cancer Society grant award for CU Cancer Center member Lisa McKenzie PhD, MPH.

28 Jun 2021

Three CU researchers recognized for contributions to immunotherapy in childhood cancer

Three members of the University of Colorado Cancer Center and a longstanding supporter of the campus are part of a group of more than 200 researchers nationwide who were recognized in April with the Team Science Award from the American Association for Cancer Research.

23 Jun 2021

Researchers develop new therapeutic approach for treating acute myeloid leukemia

Leukemia stem cells are rare cells that can renew themselves while continuing to generate malignant cells known as leukemic blasts. These cells are difficult to eradicate using chemotherapy drugs and frequently lead to recurrence of leukemia.

22 Jun 2021

New discovery in Ewing sarcoma may prevent tumor metastasis from occurring

A new discovery in Ewing sarcoma, an aggressive and often fatal childhood cancer, has uncovered the potential to prevent cancer cells from spreading beyond their primary tumor site.

1 Jun 2021

Study may lead to new treatments that eliminate cancer cells without harming other body cells

Normal cells usually have multiple solutions for fixing problems. For example, when DNA becomes damaged, healthy white blood cells can use several different strategies to make repairs.

28 May 2021

Blocking TGFβ1 could improve hematopoiesis in AML patients, indicates study

Bone marrow failure due to acute myeloid leukemia (AML) is a significant factor behind the disease's high rate of morbidity and mortality. Previous studies in mice suggest that AML cells inhibit healthy hematopoietic (blood) stem and progenitor cells (HSPC).

20 May 2021

‘Kicking you when you’re down’: Many cancer patients pay dearly for parking

For cancer patients, the road from diagnosis to survivorship feels like a never-ending parade of medical appointments: surgeries, bloodwork, chemotherapy, radiation treatments, scans.

17 May 2021

Researchers identify new immunotherapy treatment target for acute myeloid leukemia in children

Researchers have identified a gene expressed in children with acute myeloid leukemia (AML) that could serve as a new immunotherapy treatment target, according to a new study published today in Blood Advances, a journal of the American Society of Hematology.

5 May 2021

Antiviral T cells safe, effective as off-the-shelf therapy for painful complication after stem cell transplants

A Phase II trial led by researchers at The University of Texas MD Anderson Cancer Center found that BK virus (BKV)-specific T cells from healthy donors were safe and effective as an off-the-shelf therapy for BKV-associated hemorrhagic cystitis (BKV-HC), a painful complication common after allogeneic stem cell transplants for patients with leukemia or lymphoma.

30 Apr 2021

Novel compound in avocados may offer a route to better leukemia treatment

A compound in avocados may ultimately offer a route to better leukemia treatment, says a new University of Guelph study.

29 Apr 2021

Single dose of Pfizer-BioNTech COVID-19 vaccine induces immunity in CML patients

Researchers in the UK have shown that a single dose of the Pfizer-BioNTech vaccine against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) induced antibody and cellular responses in patients with chronic myeloid leukemia (CML) who were taking tyrosine kinase inhibitors.

25 Apr 2021

Ponatinib identified as a potent inhibitor of SARS-CoV2-induced cytokine storm

Researchers at the Human Biology Division, Fred Hutchinson Cancer Research Center in Washington, United States, found that the FDA-approved, multi-kinase inhibitor Ponatinib is a potent inhibitor of the N-terminal domain (NTD) -mediated cytokine storm. Ponatinib is an oral drug used for the treatment of chronic myeloid leukemia (CML).

14 Apr 2021

Transposons can protect against certain blood cancers

New research has uncovered a surprising role for so-called "jumping" genes that are a source of genetic mutations responsible for a number of human diseases.

9 Apr 2021